The Online Investor
Trillium Therapeutics Inc (TRIL)

Trillium Therapeutics is a clinical stage immuno-oncology company developing therapies for the treatment of cancer. Co.'s primary program, TTI-621, is a SIRPaFc fusion protein that consists of the extracellular CD47-binding domain of human signal regulatory protein alpha (SIRPa) linked to the Fc region of a human immunoglobulin G1 (IgG1). It is designed to act as a soluble decoy receptor, preventing CD47 from delivering its inhibitory signal. Co. is also developing a second SIRPaFc fusion protein, TTI-622, which consists of the extracellular CD47-binding domain of human SIRPa linked to a human immunoglobulin G4 Fc region, which has a decreased ability to engage Fc receptors than an IgG1 Fc.
Company Name: 
Trillium Therapeutics Inc
Website: 
www.trilliumtherapeutics.com
Sector: 
Drugs & Pharmaceuticals
Quotes delayed 20 minutes

Email EnvelopeFree TRIL Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts

Hold (2.33 out of 4)
100th percentile
(ranked higher than approx. 100% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Trillium Therapeutics Inc (TRIL) Page | The Online Investor Page | www.TheOnlineInvestor.com

Copyright © 1998 - 2024, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.